Henan Lingrui Pharmaceutical Co., Ltd.
600285.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.15B
Close$
Share Statistics
| Market cap | $11.15 Billion |
|---|---|
| Enterprise Value | $10.92 Billion |
| Dividend Yield | $1.10 (5.60%) |
| Earnings per Share | $1.34 |
| Beta | -0.01 |
| Outstanding Shares | 567,115,486 |
Return
| Return on Equity | 24.14% |
|---|---|
| Return on Assets | 13.56% |
| Return on Invested Capital | 26.69% |
Valuation & Multiples
| P/E Ratio | 14.25 |
|---|---|
| PEG | -416.47 |
| Price to Sales | 3.28 |
| Price to Book Ratio | 3.93 |
| Enterprise Value to Revenue | 2.8 |
| Enterprise Value to EBIT | 12.22 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.02 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.04 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Henan Lingrui Pharmaceutical Co., Ltd.
2,789 employees
CEO: Wei Xiong Established in 1992 and headquartered in Xinyang, China, Henan Lingrui Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products throughout the Chinese market. The company offers a broad catalog o...